[go: up one dir, main page]

PE20251287A1 - Compuestos aromaticos que contienen boro y analogos de insulina relacionados - Google Patents

Compuestos aromaticos que contienen boro y analogos de insulina relacionados

Info

Publication number
PE20251287A1
PE20251287A1 PE2024002571A PE2024002571A PE20251287A1 PE 20251287 A1 PE20251287 A1 PE 20251287A1 PE 2024002571 A PE2024002571 A PE 2024002571A PE 2024002571 A PE2024002571 A PE 2024002571A PE 20251287 A1 PE20251287 A1 PE 20251287A1
Authority
PE
Peru
Prior art keywords
compounds containing
aromatic compounds
containing boron
amine
insulin analogues
Prior art date
Application number
PE2024002571A
Other languages
English (en)
Inventor
Jingxin Liang
Diao Chen
Jack Joseph Steele
Ryan Kelly Spencer
Mirna Ekram Anwar Shaker
Alborz Mahdavi
Sachitanand Mali
Original Assignee
Protomer Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protomer Tech Inc filed Critical Protomer Tech Inc
Publication of PE20251287A1 publication Critical patent/PE20251287A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se refiere a compuestos que incluyen uno o mas grupos aromaticos que contienen boro y metodos para producirlos, composiciones farmaceuticas que los comprenden, y su uso en la prevencion y el tratamiento de enfermedades y trastornos caracterizados por niveles elevados de glucosa, tales como hiperglucemia, diabetes tipo 2, obesidad, entre otros. Se trata de un compuesto de Formula I, o un estereoisomero o una mezcla de estereoisomeros, o sal farmaceuticamente aceptable de este, en donde: X1 comprende: i. una sustancia farmacologica que comprende una amina; ii. una amina configurada para conjugarse covalentemente con una sustancia farmacologica; o iii. NH2 u OH; Z1a es de 1 a 50 aminoacidos conectados entre si mediante enlaces amida o peptidicos; Z1b es un enlazador de molecula pequena; Z1c se selecciona independientemente de las Formulas FF12, FF12A, FF12B, entre otros; cada m' es 0 o 1; cada n' es 0; cada o' es 1; cada p' es 1, 2, 3, 4, 5, 6, 7, 8, 9, o 10; y cada q' es 1, 2, 3, 4, o 5.
PE2024002571A 2022-05-18 2023-05-17 Compuestos aromaticos que contienen boro y analogos de insulina relacionados PE20251287A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263364893P 2022-05-18 2022-05-18
PCT/US2023/067089 WO2023225534A1 (en) 2022-05-18 2023-05-17 Aromatic boron-containing compounds and related insulin analogs

Publications (1)

Publication Number Publication Date
PE20251287A1 true PE20251287A1 (es) 2025-05-14

Family

ID=86760138

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024002571A PE20251287A1 (es) 2022-05-18 2023-05-17 Compuestos aromaticos que contienen boro y analogos de insulina relacionados

Country Status (16)

Country Link
US (2) US12139502B2 (es)
EP (1) EP4525919A1 (es)
JP (1) JP2025521112A (es)
KR (2) KR20250004935A (es)
CN (1) CN119677541A (es)
AR (1) AR129357A1 (es)
AU (1) AU2023272483A1 (es)
CA (1) CA3253643A1 (es)
CL (1) CL2024003507A1 (es)
CO (1) CO2024015524A2 (es)
DO (1) DOP2024000242A (es)
IL (1) IL317049A (es)
MX (1) MX2024014216A (es)
PE (1) PE20251287A1 (es)
TW (1) TW202409070A (es)
WO (1) WO2023225534A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024251658A1 (en) * 2023-04-11 2025-09-18 Protomer Technologies, Inc. Compounds containing one or more diboronates and related insulin analogs
AU2024295902A1 (en) 2023-07-18 2026-01-15 Novo Nordisk A/S Pharmaceutical compositions of insulin derivatives

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US906028A (en) 1908-03-27 1908-12-08 Herbert E Jennison Adjustable foot-block for radiators.
US4421685A (en) 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
CA1339955C (en) 1986-10-14 1998-07-14 Richard Eugene Heiney Process for transforming a human insulin precursor to human insulin
US4888414A (en) 1987-04-09 1989-12-19 Board Of Regents, University Of Texas System Insulin-binding peptides and uses thereof
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
YU18596A (sh) 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
KR20010024556A (ko) 1997-10-24 2001-03-26 피터 지. 스트링거 불용성 인슐린 조성물
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
EP1044016B1 (en) 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
EP1453860A2 (en) 2001-12-02 2004-09-08 Novo Nordisk A/S Novel glucose-dependant insulins
AU2003248370A1 (en) 2002-02-27 2003-09-09 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
US20070219346A1 (en) 2002-04-22 2007-09-20 Mcgill University Glucose sensor and uses thereof
EP1506230B1 (en) 2002-05-07 2011-01-19 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
ATE525395T1 (de) 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
JP2007518811A (ja) 2004-01-23 2007-07-12 カリフォルニア インスティチュート オブ テクノロジー 操作されたタンパク質、ならびに作製方法および使用方法
SG135176A1 (en) 2004-02-02 2007-09-28 Ambrx Inc Modified human four helical bundle polypeptides and their uses
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
MX2007007581A (es) 2004-12-22 2007-07-24 Ambrx Inc Composiciones de amino acil-arnt sintetasa y sus usos.
US20100247433A1 (en) 2005-10-14 2010-09-30 California Institute Of Technology Use of non-canonical amino acids as metabolic markers for rapidly-dividing cells
US20070099820A1 (en) 2005-10-19 2007-05-03 Smartcells, Inc. Polymer-drug conjugates
PL1999259T3 (pl) 2006-03-03 2015-01-30 California Inst Of Techn Specyficzne miejscowo wprowadzanie aminokwasów do cząsteczek
AU2007248680C1 (en) 2006-05-02 2014-01-23 Allozyne, Inc. Non-natural amino acid substituted polypeptides
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
WO2008033847A2 (en) 2006-09-11 2008-03-20 Emory University Modified protein polymers
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
ES2346178T3 (es) 2007-07-31 2015-11-02 Affibody Ab Nuevas composiciones, procedimientos y usos de unión de la albúmina
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
ES2563553T3 (es) 2008-04-01 2016-03-15 Novo Nordisk A/S Conjugados de insulina-albúmina
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
EP2408470A4 (en) 2009-03-20 2012-08-29 Smartcells Inc SOLUBLE NONDEPOT INSULIN CONJUGATE AND ITS USE
EP2408808A4 (en) 2009-03-20 2015-05-06 Smartcells Inc TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE
DK3702371T5 (da) 2009-03-25 2024-08-26 Genentech Inc Anti-FGFR3-antistoffer og fremgangsmåder ved anvendelse af disse
US8614185B2 (en) 2009-05-04 2013-12-24 Centocor Ortho Biotech Inc. Fusion proteins of alpha-MSH derivatives and Fc
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
SG192671A1 (en) 2011-02-09 2013-09-30 Glaxosmithkline Llc Lyophilized formulations
WO2013015697A1 (en) * 2011-07-28 2013-01-31 Mabion S.A. A recombinant protein, a polynucleotide encoding it as well as a method of obtaining insulin or its an analogue
EP2814459A1 (en) 2012-02-17 2014-12-24 Massachusetts Institute Of Technology Self-regulated peptide hydrogel for insulin delivery
US9996862B2 (en) 2012-07-23 2018-06-12 @Pay Ip Holdings Llc Point of sale email-based e-commerce
WO2014093696A2 (en) 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
WO2014170898A1 (en) 2013-04-18 2014-10-23 Bar-Ilan University Non-immunogenic and nuclease resistant nucleic acid origami devices and compositions thereof
BR112016007176A2 (pt) 2013-10-04 2018-01-23 Merck Sharp & Dohme conjugado, composição, usos de um conjugado e de uma composição, e, método para tratar um indivíduo que tem diabete
WO2015191705A1 (en) 2014-06-10 2015-12-17 California Institute Of Technology Non-canonical insulins and their uses
HK1247836A1 (zh) 2015-03-13 2018-10-05 Case Western Reserve University 含有葡萄糖调节的构象转换器的胰岛素类似物
US11052133B2 (en) 2015-05-06 2021-07-06 Protomer Technologies, Inc. Glucose responsive insulins
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
WO2017070617A1 (en) 2015-10-21 2017-04-27 Case Western Reserve University Diol-modified insulin analogues containing a glucose-regulated conformational switch
JOP20190273A1 (ar) 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
MA50552A (fr) 2017-11-09 2020-09-16 Novo Nordisk As Dérivés de liaison à l'albumine sensibles au glucose
US20210214412A1 (en) 2018-04-16 2021-07-15 University Of Utah Research Foundation Glucose-responsive insulin
MX2021010988A (es) 2019-03-29 2021-10-01 Novo Nordisk As Derivados de insulina sensibles a la glucosa.
US20220288213A1 (en) 2019-07-31 2022-09-15 Thermalin Inc. Insulin analogues with glucose regulated conformational switch
KR20220161422A (ko) 2020-03-31 2022-12-06 프로토머 테크놀로지스 인크. 비시날 디올에 대한 선택적인 반응을 위한 접합체
CN113105536B (zh) * 2020-09-11 2023-07-18 美药星（南京）制药有限公司 一种新甘精胰岛素原及其制备甘精胰岛素的方法
JP2024500284A (ja) * 2020-11-19 2024-01-09 プロトマー・テクノロジーズ・インコーポレイテッド 芳香族ホウ素含有化合物及びインスリン類似体
WO2022235691A1 (en) * 2021-05-03 2022-11-10 The Trustees Of Indiana University Molecular design of glucose sensors in glucose-responsive insulin analogues

Also Published As

Publication number Publication date
DOP2024000242A (es) 2024-12-15
AR129357A1 (es) 2024-08-14
IL317049A (en) 2025-01-01
CN119677541A (zh) 2025-03-21
CA3253643A1 (en) 2023-11-23
KR20250004935A (ko) 2025-01-08
KR20250005573A (ko) 2025-01-09
CL2024003507A1 (es) 2025-04-25
AU2023272483A1 (en) 2024-12-12
EP4525919A1 (en) 2025-03-26
WO2023225534A1 (en) 2023-11-23
US20240425528A1 (en) 2024-12-26
TW202409070A (zh) 2024-03-01
MX2024014216A (es) 2024-12-06
US12139502B2 (en) 2024-11-12
CO2024015524A2 (es) 2024-11-28
US20230374045A1 (en) 2023-11-23
JP2025521112A (ja) 2025-07-08

Similar Documents

Publication Publication Date Title
PE20251287A1 (es) Compuestos aromaticos que contienen boro y analogos de insulina relacionados
US6552043B1 (en) Benzimidazolinyl piperidines as CGRP ligands
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
US20120004309A1 (en) Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof
BRPI0613984A2 (pt) peptìdios para uso no tratamento da obesidade, seu uso e composição farmacêutica compreendendo os mesmos
AR035710A1 (es) Compuesto derivado de beta-aminoacidos ciclicos, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento para el tratamiento de una enfermedad mediada por mmps, tnf, agrecanasa y combinaciones de los mismos
PE20231948A1 (es) Compuestos aromaticos que contienen boro y analogos de insulina
JP2024059693A (ja) ５．８～８．５のｐＩを有する少なくとも１つの基礎インスリン、および、カルボキシレート電荷および疎水性ラジカルを有するコポリアミノ酸を含むｐＨ７を有する注射溶液
UY33605A (es) Profarmacos que comprenden un conjugado de conector de exendina
AR067475A1 (es) Antagonistas no basico s del receptor de la hormona concentradora de melanina 1
CN111565710A (zh) 包含胰淀素、胰淀素受体激动剂或胰淀素类似物以及共聚氨基酸的呈可注射水溶液形式的组合物
US8198327B2 (en) Fatty acid amides and uses thereof
CN102573794B (zh) 供生理注射用的半胱氨酸
CN117567639A (zh) 用于细胞内递送装订肽的多肽缀合物
KR20200101428A (ko) 최적화된 화합물
AU2005265164A2 (en) Non-natural amino acids
US20080293685A1 (en) Spiro and other derivatives of diamondoids possessing therapeutic activity in the treatment of viral disorders
IL263388A (en) Diprobooks: A new and powerful group of tlr agonists
RU2010109416A (ru) Замещенные тетрагидронафталины, способ их получения и их применение в качестве лекарственных средств
AR035942A1 (es) Antagonistas de somatostatina, un metodo in vitro de enlace de uno o mas receptores de somatostatina, uso de dichos antagonistas para la preparacion de medicamentos y un metodo in vitro para produccion de imagenes de celulas que tienen dichos receptores.
EP3166960B1 (en) Low substituted polymyxins and compositions thereof
PT100756B (pt) Novos derivados de gangliosidos, processo para a sua preparacao e composicoes farmaceuticas que os contem
EA201070603A1 (ru) Лекарственное средство, активное в отношении невропатической боли
ES2773376T3 (es) Amidas de ácidos grasos, composiciones y procedimientos de uso
RU2010104473A (ru) Аминоацильные пролекарства в качестве фармацевтических действующих веществ для лечения тромбоэмболических заболеваний